Abstract: Several in vitro investigations have demonstrated that anticoagulant effects of fibrinogenolytic snake venom metalloproteinases have been abrogated in human plasma by modifying fibrinogen with iron (Fe) and carbon monoxide (CO) to prevent catalysis or by directly inhibiting these enzymes with CO. To translate these findings, we chose to assess the rabbit as a model of envenomation with Crotalus atrox venom. It was determined with thrombelastography that 15 times the concentration of venom noted to compromise coagulation in plasma in vitro was required to cause coagulopathy in vivo, likely secondary to venom binding to blood cells and being cleared from the circulation rapidly. Unlike human plasma, rabbit plasma pre-treated with Fe/CO was not protected from fibrinogenolysis by venom. Consequently, the administration of purified human fibrinogen (with or without Fe/CO) would be required before venom administration to rabbits. Of greater interest, venom exposed to CO had complete loss of fibrinogenolytic effect in rabbit plasma and partial loss of activity in whole blood, indicative of unbinding of CO from venom and binding to haemoglobin. Thus, venom exposed to CO could remain partially or completely inhibited in whole blood long enough for clearance from the circulation, allowing rabbits to be a useful model to test the efficacy of regional CO administration to the bite site. Future investigations are planned to test these novel approaches to attenuate venom-mediated coagulopathy in the rabbit.
Extensive in vitro investigation of novel therapeutic methods to abrogate the fibrinogenolytic/thrombin-like activity of snake venom metalloproteinases (SVMP) and snake venom serine proteases (SVSP) has been pursued by our laboratory recently [1] [2] [3] [4] [5] [6] [7] . The first method was to modify fibrinogen in human plasma by exposure to iron (Fe) and carbon monoxide (CO), rendering this 'stealth' fibrinogen less recognizable to SVMPs [1] [2] [3] [4] . The second approach was direct, isolated exposure of SVMP and SVSP to CO in vitro, with subsequent loss of associated fibrinogenolytic or thrombin-like activity observed in human plasma [4] [5] [6] [7] . When combined, the modification of fibrinogen with Fe/CO and direct inhibition of SVMP/SVSP have potential to complement traditional antivenom administration when treating envenomed patients.
However, the next step in developing this potential therapeutic paradigm requires the identification of a pre-clinical animal model that haemostatically responds to envenomation and exposure to Fe/CO in a manner similar to human beings. The model should permit facile vascular access, envenomation and sequential coagulation assessments of interventions. One such potential model is the New Zealand White (NZW) rabbit, the coagulation system of which responds kinetically (assessed by thrombelastography) and ultrastructurally (assessed by scanning electron microscopy) to thrombin in a manner similar to human haemostasis as recently reviewed [8] . Further, rabbit fibrinogen is modified by CO exposure, with enhanced coagulation observed as in human beings [9] ; and lastly, ear veins and arteries are easily accessed in rabbits, which can subsequently be utilized to sedate and envenom the animal with serial blood collections possible hours to days if needed [9] [10] [11] [12] [13] [14] . In sum, the NZW rabbit potentially possessed the features required to evaluate further the utility of Fe/CO-exposed fibrinogen and direct CO inhibition as methods to reduce SVMP/SVSP-mediated compromise of coagulation.
Thus, the purposes of this investigation were (1) generate, in vitro, a Crotalus atrox venom-mediated coagulation degradation concentration-response data set in rabbit whole blood to guide in vivo experimental envenomation; (2) determine, in vitro, the rabbit whole blood and plasma coagulation kinetic response to Fe; (3) determine, in vitro, if Fe/CO pre-treatment protects rabbit whole blood and plasma coagulation kinetics from venom-mediated degradation; (4) determine the reversibility of CO-mediated inhibition of venom in vitro rabbit whole blood and plasma and in vivo in envenomed mice; and (5) determine the thrombelastographic response to envenomation in vivo in the rabbit with a dose of venom that provides a significant degradation of coagulation. The venom used was collected from C. atrox, as the plasmatic thrombelastographic response to this fibrinogenolytic venom and attenuation of its effects by Fe and CO in plasma and direct inhibition of this venom by CO have been previously well defined in human beings in vitro [2, 5] . Lastly, these matters were defined with thrombelastographic approaches and with the well-validated Spearman-Karber murine model to determine 50% lethal dose (LD 50 ) as recently described [15] .
Materials and Methods
Rabbits. Eight male NZW rabbits (1.9-2.2 kg) were obtained from Charles River Laboratories (San Diego, CA, USA), then maintained within our animal facilities and allowed food and water ad libitum. All subsequently described experimentations were performed with blood obtained from these eight animals over a 3-month period, including the final in vivo venom-mediated degradation of coagulation dose-response experiments. Finally, our Institutional Animal Care and Utilization Committee approved all procedures involving these rabbits (protocol #16-165).
Rabbit whole blood and plasma collection and processing. Rabbits were briefly restrained within the animal facility and had one ear closely clipped and cleaned with a 70% isopropyl alcohol pad. A 22-G plastic catheter was placed in the distal third of the central ear artery, and 4.5 ml of whole blood collected into a sodium citrate containing tube (9 parts blood to 1 part 0.105 M sodium citrate). The catheter was then removed and haemostasis obtained with 5-10 min. of gentle pressure. Blood collections occurred weekly, alternating ears. If whole blood experiments were planned, then the sample was transported to the laboratory. However, samples destined for plasmabased experiments were subsequently centrifuged at 30009 g for 15 min. at room temperature, with plasma decanted, aliquoted and stored at À80°C prior to experimentation.
C. atrox venom and chemicals. Two hundred mg of lyophilized C. atrox venom was obtained from the National Natural Toxins Research Center (NNTRC) at Texas A&M University-Kingsville, Kingsville, TX, USA. The venom was reconstituted in calcium-free phosphate-buffered saline (PBS, Sigma-Aldrich, Saint Louis, MO, USA) at a concentration of 50 mg/ml, aliquoted and stored at À80°C until experimentation. CORM-2 (tricarbonyldichlororuthenium (II) dimer, a CO-releasing molecule), ferric chloride (FeCl3, 99.9% pure) and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich, Saint Louis, MO, USA. Midazolam (5 mg/ml) was purchased from Akorn, Inc., Lake Forest, IL, USA, and pentobarbital/phenytoin (390 and 50 mg/ml, respectively) was obtained from Henry Schein Animal Health, Dubin, OH, USA.
General thrombelastographic analyses. The specific volumes of subsequently described whole blood and plasma samples vary by experimental series but were approximately 360 ll. All sample mixtures were placed in a disposable cup in a computer-controlled thrombelastograph â haemostasis system (Model 5000; Haemonetics Inc., Braintree, MA, USA) at 39°C, the normal temperature of the NZW rabbit [16] . The following elastic modulus-based parameters previously described [1] [2] [3] [4] [5] [6] [7] [8] [9] were determined: time to maximum rate of thrombus generation (TMRTG), this is the time interval (min.) observed prior to maximum speed of clot growth; maximum rate of thrombus generation (MRTG), this is the maximum velocity of clot growth observed (dynes/cm 2 /sec.); and total thrombus generation (TTG, dynes/cm 2 ), the final viscoelastic resistance observed after clot formation. Data were collected for 15-40 min., depending on the experimental series.
Generation of in vitro C. atrox venom-mediated coagulation degradation concentration-response data in rabbit whole blood. The sample mixture volume for these experiments was 359.6 ll. Sample composition consisted of 326 ll of citrated whole blood, 3.6 ll of PBS or venom, and 10 ll of tissue factor reagent (TF, 0.1% final concentration in distilled water; Diagnostica Stago S.A.S., Asnieres sur Seine, France). The concentrations of venom tested guided by preliminary work were 0, 1, 2 and 4 lg/ml; plasma, TF and venom were mixed in the thrombelastograph cup and allowed to incubate at 39°C for 30 min. After incubation, 20 ll of 200 mM CaCl 2 (Haemonetics Inc.) was added and mixed with the sample, with data collection commenced and continued for 30 min.
Determination of rabbit whole blood and plasma coagulation kinetic response to Fe in vitro. The sample mixture volume for these experiments was 359.4 ll. Sample composition consisted of 336 ll of citrated whole blood or plasma mixed with 3.6 ll of PBS or FeCl 3 (final concentration 10 lg/ml). This concentration of Fe has been demonstrated to be the minimum concentration that results in the maximal response kinetically in human plasma [17] . Samples were incubated at 39°C for 5 min. After incubation, 20 ll of 200 mM CaCl 2 was added and mixed with the sample, with data collection commenced and continued for 30 min.
Determination of Fe/CO pre-treatment protection of rabbit whole blood and plasma coagulation kinetics from C. atrox venom-mediated degradation in vitro. The sample mixture volume for these experiments was 360.8 ll. Sample composition consisted of 320 ll of whole blood or plasma; 3.6 ll of PBS or iron (10 lM final concentration); 3.6 ll of DMSO or CORM-2 (100 lM final concentration); 10 ll of TF; 3.6 ll of PBS or venom (1.5 lg/ml final concentration in whole blood and 0.5 lg/ml final concentration in plasma). Fe, CORM-2 and TF were added to whole blood or plasma and mixed, followed by a 3-min. incubation at 39°C. Venom was then added, and after mixing, another 5-min. incubation at 39°C was performed. Lastly, 20 ll of 200 mM CaCl 2 was added, rapidly mixed, with immediate data collection commenced. Data were collected for 40 min. in experiments with whole blood, whereas data were collected for 15 min. in plasma-based work.
Determination of the reversibility of CO-mediated inhibition of C. atrox venom in vitro and in vivo. In vitro rabbit experiments -To determine whether CO binding to fibrinogenolytic enzymes in C. atrox venom was reversible secondary to the presence of the CO binding molecule haemoglobin, we compared and contrasted the extent of CO-mediated inhibition of venom activity in rabbit whole blood and plasma. The sample mixture volume for these experiments was 360.2 ll. Sample composition consisted of 320 ll of whole blood or plasma; 3.4 ll of PBS; 3.4 ll of DMSO; 10 ll of TF; 3.4 ll of PBS or venom (1.5 lg/ml final concentration in whole blood and 0.5 lg/ml final concentration in plasma) exposed to DMSO or CORM-2 (300 lM). PBS, DMSO and TF were added to whole blood or plasma and mixed. Venom was placed into PBS and exposed to DMSO or 300 lM CORM-2 for 5 min. at 39°C. Venom was then added to whole blood or plasma samples, and after mixing, another 5-min. incubation at 39°C was performed. Lastly, 20 ll of 200 mM CaCl 2 was added, rapidly mixed, with immediate data collection commenced. Data were collected for 40 min. in experiments with whole blood, whereas data were collected for 15 min. in plasma-based work. In vivo murine lethal dose 50% (LD 50 ) experiments -To determine whether CO-mediated inactivation of C. atrox venom is reversible or irreversible, BALB/c mice (18-20 g ) were injected with CO-unmodified or CO-modified venom via tail vein as previously described [15] at the NNTRC, Texas A&M University-Kingsville, Kingsville, Texas, USA. In brief, venom in PBS was exposed to DMSO or 100 lM CORM-2 (1% v/v addition) for 5 min. at room temperature, with 0.025, 0.05, 0.1, 0.2 or 0.4 mg of DMSO-or CORM-2-exposed venom injected into the mice. Each dose was administered to n = 8 mice, with death after 48 hr the primary outcome variable. This bioassay is a standard service and is approved by the IACUC at the NNTRC (IACUC Protocol #2015-12-09-A6).
Determination of an in vivo dose of C. atrox venom in the rabbit that results in a significant and consistent thrombelastographically determined degradation of whole blood coagulation. These experiments were conducted within the Coagulation Laboratory of the Department of Anesthesiology secondary for the need to be near our thrombelastograph analysers as we were collecting fresh whole blood that needs to be analysed within just a few minutes after collection. Rabbits were briefly restrained and had one ear closely clipped and cleaned with a 70% isopropyl alcohol pad. A 22-G plastic catheter was placed in the distal third of the central ear artery and another similar catheter placed in the marginal ear vein. The animals were sedated intravenously with 1 mg/kg midazolam (Akorn Inc., Lake Forest, IL, USA), with supplemental doses of 0.5-1 mg/kg provided over the hour of experimentation to maintain sedation. One forepaw was subsequently closely clipped, with a pulse oximeter probe placed to monitor heart rate (HR, beats/minute) and % arterial oxygenation (SpO 2 ) with a Radical 7 â monitor using a Rainbow â R1 25L probe capable of detecting % carboxyhaemoglobin that was manufactured and provided by Masimo Corporation (Irvine, CA, USA). Heart rate (HR) and SpO 2 were recorded at baseline and every 15 min. thereafter until the end of the experiment. A baseline 1-ml arterial whole blood sample was collected, with 350 ll placed into a thrombelastographic cup with 10 ll of TF within 3 min. of collection. The sample was mixed and data collected at 39°C for 30 min. C. atrox venom suspended in 3 ml of PBS was then administered intravenously over 3 min., with subsequent recordings of HR and SpO 2 with collection of 1 ml whole blood samples conducted every 15 min. for 1 hr. Given the results of the preceding in vitro whole blood dose-response experiments and the assumption of the estimated blood volume (EBV) of the rabbit being 65 ml/kg [18] , three different doses of venom were tested (130, 1000 and 500 lg/kg) with n = 1 rabbit, with the subsequent five rabbits administered 500 lg/kg for a total of n = 6 for this dose. At the end of the experiment, the rabbits were killed with intravenous administration of 1 ml of pentobarbital/phenytoin (390/50 mg/ml; Henry Schein).
Statistical analyses. Data are presented as mean AE SD. All conditions or experimental groups were represented by n = 6-8 different samples/individuals, as this provides a statistical power >0.8 with p < 0.05 using this thrombelastographic methodology [1] [2] [3] [4] [5] [6] [7] [8] [9] . A commercially available statistical program was used for two-tailed, paired Student's t-tests or one-way repeated measures analyses of variance (ANOVA), followed by Holm-Sidak post hoc analyses as appropriate (SigmaStat 3.1; Systat Software, Inc., San Jose, CA, USA). Graphics depicting coagulation kinetic data were generated with a commercially available program (OrigenPro 2017; OrigenLab Corporation, Northampton, MA, USA). p < 0.05 was considered significant.
Results
Generation of in vitro C. atrox venom-mediated coagulation degradation concentration-response data in rabbit whole blood.
Data from these experiments, analysed with one-way repeated measures ANOVA, are displayed in fig. 1 . With regard to TMRTG, there was a significant, concentration-dependent prolongation of this parameter value by venom exposure, with all concentrations of venom associated with increases in TMRTG. In contrast, MRTG and TTG values of samples exposed to venom significantly decreased compared with samples without venom exposure at concentrations ≥2 lg/ml. Taken as a whole, all thrombelastographic parameters were significantly affected at a venom concentration of 2 lg/ml, which would translate to an in vivo administration of 130 lg/kg intravenously with EBV of 65 ml/kg.
Determination of rabbit whole blood and plasma coagulation kinetic response to Fe in vitro. Data from these experiments are found in table 1 and were analysed with two-tailed, paired t-tests. Fe exposure resulted in a significant decrease in TMRTG values, increase in MRTG values and increase in TTG values in whole blood. In sharp contrast, Fe exposure did not have any significant effect on rabbit plasma coagulation kinetics, which is also in complete contrast to the response seen in human plasma [17] . Thus, there appeared to be no important interaction of Fe with rabbit fibrinogen, but it appeared that platelet activity in whole blood might be enhanced in rabbits by Fe. Fig. 1 . Generation of in vitro venom-mediated coagulation degradation concentration-response data in rabbit whole blood. Data are presented as mean AE SD. TMRTG, time to maximum rate of thrombus generation (min.); MRTG, maximum rate of thrombus generation (dynes/cm 2 / sec.); TTG, total thrombus generation (dynes/cm 2 ). Ãp < 0.01 versus 0 lg/ml venom; †p < 0.01 versus 1 lg/ml venom; ‡p < 0.01 versus 2 lg/ml venom.
Determination of Fe/CO pre-treatment protection of rabbit whole blood and plasma coagulation kinetics from C. atrox venom-mediated degradation in vitro. The results of these experiments, analysed with one-way repeated measures ANOVA, are depicted in figs 2 and 3. Whole blood data are found in fig. 2 , and plasma data are displayed in fig. 3 . Pre-treatment with Fe/CO did not significantly prevent venom-mediated degradation of coagulation kinetics in either rabbit whole blood or plasma.
Determination of the reversibility of CO-mediated inhibition of C. atrox venom in vitro and in vivo. Experiments involving rabbit plasma and whole blood are depicted in figs 4 and 5, respectively. These data were analysed with repeated measures one-way ANOVA. In fig. 4 , the venom-mediated increase in TMRTG and decrease in MRTG and TTG were significantly and completely eliminated when venom was pre-exposed to CORM-2 in rabbit plasma. In contrast, as seen in fig. 5 , whole blood samples exposed to venom pre-exposed to CORM-2 demonstrate TMRTG values significantly greater than samples not exposed to venom but significantly smaller than in samples with addition of venom without CORM-2 exposure. Further, the MRTG and TTG values of whole blood samples exposed to venom pre-exposed to CORM-2 were significantly less than samples not exposed to venom but significantly greater than in samples with addition of venom without CORM-2 exposure. In sum, the presence of red blood cells and the haemoglobin contained therein appear to have reduced the CO-mediated inhibition of C. atrox venom.
In the experiments at the NNTRC concerning exposure of C. atrox venom to CORM-2 prior to injection into mice, the LD 50 value was not significantly different between animals exposed to venom or venom pre-exposed to CORM-2. The LD 50 value in both experimental series was 3.7 mg/kg.
Determination of an in vivo dose of C. atrox venom in the rabbit that results in a significant and consistent thrombelastographically determined degradation of whole blood coagulation. These experiments were performed last in this investigation, and at this point, the weight of the rabbits was 3.4 AE 0.3 kg.
The first rabbit administered venom in vivo received 130 lg/ kg (calculated instantaneous 2 lg/ml whole blood concentration) demonstrated no adverse effects clinically and demonstrated no discernable change in TMRTG, MRTG or TTG after venom injection. The second rabbit was administered the largest concentration of this particular venom noted to be nonlethal, 1000 lg/kg (calculated instantaneous 15.4 lg/ml whole blood concentration) [10] ; in this case, there were still no adverse clinical effects noted, but all whole blood samples collected after envenomation demonstrated no coagulation. The third and all five subsequent rabbits were administered 500 lg/kg (calculated instantaneous 7.7 lg/ml whole blood concentration), as significant degradation of whole blood coagulation kinetics were observed without the animals becoming incoagulable. These data were analysed with repeated measures one-way ANOVA /cm 2 ). Control, no venom or Fe/CO addition to whole blood sample; V, venom (1.5 lg/ml final concentration) addition; V+Fe/CO, venom addition to whole blood pre-exposed to iron (10 lM final concentration) and CORM-2 (100 lM). Ãp ≤ 0.001 versus Control.
venom were 97 AE 1, 96 AE 2, 97 AE 2, 95 AE 2 and 97 AE 2, respectively; there was no significant change in SpO 2 throughout experimentation.
Thrombelastographic data are depicted in fig. 6 . After envenomation, there was a significant increase in TMRTG values (2.6 times on average), decrease in MRTG values (77% on average) and decrease in TTG values (68% on average) at all time-points; further, the change in these parameter values was not significantly different throughout the period after venom injection.
Discussion
Our investigation was successful in large part in defining the utility and limitations of the rabbit as a model of envenomation with fibrinogenolytic enzymes as assessed by thrombelastography. It was determined that there is a concentration-dependent degradation of whole blood coagulation by C. atrox venom in vitro and in vivo, and contributors to resistance to ongoing fibrinogenolysis were identified. This coagulopathy is mediated primarily by fibrinogenolysis by well-characterized metalloproteinases in this particular venom [19, 20] , and while some mild inhibition of platelet aggregation by inhibition/degradation of glycoprotein Ib [21] and a IIb b 1 [22] has been documented with enzymes contained in C. atrox venom, there is documentation that enzymes of this venom do not compromise platelet glycoprotein IIb/IIIa [23] . This is important, as platelet binding to fibrin polymers via glycoprotein IIb/IIIa is the basis for assessment of platelet-mediated effects in thrombelastography [24] . With regard to specific venom concentrations, approximately 8 times concentrations of venom are required to degrade whole blood coagulation to the same extent as seen in plasma (figs 1-3 ). It appears that cellular components of whole blood in vitro presumably bind fibrinogenolytic enzymes, preventing the enzymes from compromising coagulation. While coagulation was compromised to a somewhat greater extent in vivo ( fig. 6 ) than in vitro ( fig. 1) , there was still a nearly double concentration of venom required in vivo than in vitro to achieve this effect. Further, the fibrinogenolytic enzymatic activity appears to be cleared from the circulation within 15 min. of injection ( fig. 6) , as a plateau of compromise of coagulation function is observed thereafter. When not in the circulation, human plasma /cm 2 ). Control, no venom or Fe/CO addition to whole blood sample; V, venom (0.5 lg/ml final concentration) addition; V+Fe/CO, venom addition to whole blood pre-exposed to Fe (10 lM final concentration) and CORM-2 (100 lM). Ãp ≤ 0.001 versus Control, †p < 0.001 versus V. Fig. 4 . Determination of the reversibility of CO-mediated inhibition of C. atrox venom in plasma. Data are presented as mean AE SD. TMRTG, time to maximum rate of thrombus generation (min.); MRTG, maximum rate of thrombus generation (dynes/cm 2 /sec.); TTG, total thrombus generation (dynes/cm 2 ). Control, no venom addition to plasma sample; V, venom (0.5 lg/ml final concentration) addition to plasma sample; CO+V, venom pre-exposed to CORM-2 (300 lM final concentration) addition to plasma sample. Ãp < 0.001 versus Control, †p < 0.001 versus V.
demonstrates a continuous, time-dependent degradation of coagulation in the presence of C. atrox venom [2] ; thus, the rabbit is likely redistributing the fibrinogenolytic enzymes from the circulation and the target molecule, fibrinogen. In sum, we discerned two hereto unknown 'defences' against venom-mediated degradation of coagulation in the rabbit; binding to blood cells and redistribution from the circulation such that contact between fibrinogen and venom enzymes does not occur.
Important differences between the rabbit and human beings with regard to coagulation and potential methods to attenuate the effects of fibrinogenolytic enzymes were identified in vitro. Unlike in human beings [17] , Fe does not change the conformation of fibrinogen such that thrombin-mediated coagulation is enhanced on plasma (table 1) . Instead, it appears that platelet function is instead enhanced in the rabbit by Fea phenomenon not reported in any other species to the best of our knowledge. While thrombin-mediated plasmatic coagulation was not affected by Fe in the rabbit, it has already been shown that CO enhances coagulation in the rabbit in vitro and in vivo [9] . Thus, it was hoped that Fe/CO might in some way modify rabbit fibrinogen to make it resistant to C. atrox venom as in human plasma [2] ; however, this was not the case in either rabbit whole blood or plasma (figs 2 and 3). In sum, the rabbit cannot be used as a pre-clinical model to assess the efficacy of Fe/CO administration in vivo as a defence against venom containing fibrinogenolytic enzymes given the speciesspecific differences in fibrinogen between rabbits and human beings.
However, while rabbit fibrinogen may not be protected by Fe/CO, it appears that venom fibrinogenolytic enzymes can be inhibited to a certain extent in rabbit whole blood. Depending on the environment, inhibition of fibrinogenolytic enzymes by CO may last several minutes, as partial reversal of inhibition in rabbit whole blood still took several minutes compared to no loss of inhibition in plasma (figs 4 and 5). Transfer of CO from venom enzyme to red blood cell is the most likely mechanism; further, such a reversal demonstrates that the binding of CO to fibrinogenolytic enzymes is not irreversible. Additional evidence of reversibility is the lack of difference in LD 50 values in mice exposed to venom without or with CO exposure. While C. atrox venom-mediated death is not solely secondary to bleeding, haemorrhage plays a major role. Thus, the venom most likely had CO removed in Fig. 5 . Determination of the reversibility of CO-mediated inhibition of C. atrox venom in whole blood. Data are presented as mean AE SD. TMRTG, time to maximum rate of thrombus generation (min.); MRTG, maximum rate of thrombus generation (dynes/cm 2 /sec.); TTG, total thrombus generation (dynes/cm 2 ). Control, no venom addition to whole sample; V, venom (0.5 lg/ml final concentration) addition to whole blood sample; CO+V, venom pre-exposed to CORM-2 (300 lM final concentration) addition to whole blood sample. Ãp < 0.025 versus Control, †p < 0.005 versus V. mice in vivo in a fairly rapid fashion. While at first consideration the data seem to disfavour the use of CO administration, it may be possible to inhibit enzymes regionally (e.g. at the bite site) with CO application. If the CO-inhibited venom enzymes are blood cell bound and subsequently cleared rapidly from the circulation before CO disassociates from the enzymes, it may be possible to delay or markedly attenuate degradation of circulating fibrinogen. The level of protection would certainly depend on the amount of venom released into the circulation, the 'capacity' of the venom enzyme clearance mechanism and the adequacy of exposure of venom at the bite site to sufficient concentrations of CO. In sum, we plan future investigations to assess the viability of preventing C. atrox venom-mediated coagulopathy in vivo by exposing venom to CO to address these matters.
While the present investigation lays the ground work to pursue the alternative and complimentary therapeutic strategies to abrogate the effects of envenomation with fibrinogenolytic enzymes, there are many obstacles to overcome. Firstly, while the administration of intravenous ferric iron in the setting of iron deficiency secondary to haemodialysis is well-established [25] , the use of iron for the purposes of attenuating the effects of snake venom on coagulation has not been approved. Further, the administration of CO systemically, either by controlled inhalation or administration of carbon monoxide releasing molecules in human beings, has not been approved for any indication as yet. Lastly, while we have utilized a quintessential viper's venom in our new rabbit model, clearly other venoms with fibrinogenolytic and thrombin-like activities need to be tested as well. In sum, a great deal of future investigation will be needed to validate and translate the treatment of fibrinogen with iron and CO or the direct inhibition of SVMP/SVSP with CO into a useful clinical therapy.
In conclusion, this investigation determined the viability of the rabbit as a pre-clinical model of venom-mediated coagulopathy. Rabbit fibrinogen is not protected from fibrinogenolytic enzymes by Fe/CO exposure as is human fibrinogen [1] [2] [3] [4] [5] [6] [7] ; thus, to use the rabbit as a pre-clinical model to assess Fe/CO-mediated protection, it would be necessary to administer purified human fibrinogen to rabbits as has been performed previously [26] without or with modification by Fe/ CO prior to venom administration. However, venom enzymes exposed to CO may remain partially or completely inhibited in vivo in whole blood long enough for clearance from the circulation in the rabbit, allowing this animal to be a very useful pre-clinical model to test the efficacy of regional CO administration to the bite site. Future investigations are planned to test these novel approaches to attenuate venom-mediated coagulopathy [1] [2] [3] [4] [5] [6] [7] , translating them into the rabbit as a pre-clinical model that can have the efficacy of protection of whole blood and plasmatic coagulation assessed over time.
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